Amy joined Shattuck in October 2022 as Vice President of Clinical Operations. She brings over 25 years of drug development experience, including over 20 years in oncology clinical development. Prior to joining Shattuck, Amy was the Vice President of Clinical Operations at Aravive and NervGen Pharma. Her prior experience also includes multiple CROs and biotech companies, including OSI Pharmaceuticals, where Amy was the Clinical Operations lead for an IGF-1R inhibitor program. She has contributed to the conduct of dozens of clinical trials, ranging from Phase I to Phase III. Amy completed her BS in Cellular and Molecular Biology at the University of Michigan and later achieved a master’s degree in Bioethics from the University of Pennsylvania.